Erika P. Hamilton, MD

Articles

Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

March 8th 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab and nab-paclitaxel as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer

March 2nd 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the optimal duration of trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Dr. Hamilton on Emerging Therapies in HER2+ Breast Cancer

February 12th 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses emerging therapies in HER2-positive breast cancer.

Dr. Hamilton on Adjuvant Therapy for HER2+ Breast Cancer

February 2nd 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses adjuvant therapy for the treatment of patients with HER2-positive breast cancer.

Dr. Hamilton on the Addition of Biosimilars to Breast Oncology

December 17th 2018

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the addition of biosimilars to breast oncology.

Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer

December 21st 2017

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

October 24th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr. Hamilton on Extended Adjuvant Therapy for HER2+ Breast Cancer

October 16th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

October 8th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Dr. Hamilton on Research Needed in HER2-Positive Breast Cancer

October 6th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer

July 12th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.

Breast Cancer Milestones Are Unfolding on Several Fronts

June 20th 2016

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer

February 25th 2016

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.